Accelerating Drug Development Using Spatial Multi-omics.

Journal: Cancer discovery
Published Date:

Abstract

Spatial biology approaches enabled by innovations in imaging biomarker platforms and artificial intelligence-enabled data integration and analysis provide an assessment of patient and disease heterogeneity at ever-increasing resolution. The utility of spatial biology data in accelerating drug programs, however, requires balancing exploratory discovery investigations against scalable and clinically applicable spatial biomarker analysis.

Authors

  • Richard J A Goodwin
    Imaging and AI, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB4 0WG, U.K.
  • Stefan J Platz
    Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
  • Jorge S Reis-Filho
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Simon T Barry
    Bioscience, Early Oncology, AstraZeneca, Cambridge CB4 0WG, U.K.